Axovant Gene Therapies Ltd

Sio Gene Therapies, Inc. is a clinical-stage biopharmaceutical company, which engages in the acquisition, development, and commercialization of gene therapies for neurological diseases. Its product pipeline focuses on Parkinson's Disease, GM1 gangliosidosis, and GM2 gangliosidosis, such as Tay-Sachs disease and Sandhoff disease. The company was founded on October 31, 2014 and is headquartered in New York, NY.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Sio Gene Therapies, formerly known as Axovant, is a clinical-stage company with a singular focus on pushing the boundaries of gene therapy to develop treatments for debilitating neurodegenerative diseases, including GM1 gangliosidosis, Tay-Sachs/Sandhoff disease, and Parkinson’s disease. Sio is leveraging its foundational scientific expertise built on decades of research, extensive collaborations with leading gene therapy institutes, and a flexible vector platform to liberate patients with debilitating diseases through the transformational power of gene therapies.

-  Six-month data from low-dose cohort expected in Q4 2020   -  IND amended to include Type I (infantile onset) patients and to evaluate a higher dose   -  Expect to initiate high-dose cohort in 2H 2020

Axovant Completes Enrollment of Low-Dose Cohort in Phase 1/2 Study of AXO-AAV-GM1 and Expands Study to Include Type I (Infantile Onset) Patients with GM1 Gangliosidosis

Axovant (AXGT) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Axovant (AXGT) Moves to Strong Buy: Rationale Behind the Upgrade

Company’s balance sheet is now free of debt Company’s balance sheet is now free of debt

Axovant Announces Full Prepayment of Outstanding Loan from Hercules Capital

NEW YORK and BASEL, Switzerland, April  15, 2020  (GLOBE NEWSWIRE) -- Axovant Gene Therapies Ltd., a clinical-stage company developing innovative gene therapies for neurological diseases, today announced its collaboration with Invitae, a leading medical genetics company, in the Detect Lysosomal Storage Diseases (“Detect”) program to facilitate faster diagnoses for children with lysosomal storage disorders (“LSDs”), including GM1 gangliosidosis and GM2 gangliosidosis, also known as Tay-Sachs/Sandhoff disease. Invitae offers genetic testing and counseling at no charge to patients suspected of having an LSD.

Axovant Announces Partnership with Invitae to Increase Access to Genetic Testing and Accelerate Diagnoses of GM1 and GM2 Gangliosidosis

Axovant (AXGT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

All You Need to Know About Axovant (AXGT) Rating Upgrade to Buy

NEW YORK and BASEL, Switzerland, April  08, 2020  (GLOBE NEWSWIRE) -- Axovant Gene Therapies Ltd. (NASDAQ: AXGT), a clinical-stage company developing innovative gene therapies for neurological diseases, today provides a business and operations update during the COVID-19 pandemic.

Axovant Provides Business and Operations Update During the COVID-19 Pandemic

NEW YORK and BASEL, Switzerland, Feb.  24, 2020  (GLOBE NEWSWIRE) -- Axovant Gene Therapies Ltd. (Nasdaq: AXGT) ("Axovant") today announced the closing of its previously announced underwritten public offering of 16,631,336 common shares, including the full exercise of the underwriters’ option to purchase 2,600,000 additional common shares, at a price to the public of $3.75 per share. In addition, and in lieu of common shares, Axovant sold to a certain investor pre-funded warrants to purchase 3,301,998 common shares at a purchase price of $3.74999 per pre-funded warrant, which represents the per share public offering price for the common shares, minus the $0.00001 per share exercise price of each such pre-funded warrant. The aggregate gross proceeds to Axovant from the offering were approximately $74.7 million before deducting underwriting discounts and commissions and offering expenses.

Axovant Gene Therapies Announces Closing of $74.7 Million Public Offering of Common Shares and Prefunded Warrants, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

NEW YORK and BASEL, Switzerland, Feb.  19, 2020  (GLOBE NEWSWIRE) -- Axovant Gene Therapies Ltd. (Nasdaq: AXGT) ("Axovant") today announced the pricing of its underwritten public offering of 14,031,336 of its common shares at a price to the public of $3.75 per share. In addition, and in lieu of common shares, Axovant is offering to certain investors pre-funded warrants to purchase 3,301,998 common shares at a purchase price of $3.74999 per pre-funded warrant, which represents the per share public offering price for the common shares, minus the $0.00001 per share exercise price of each such pre-funded warrant. The aggregate gross proceeds to Axovant from the offering are expected to be approximately $65 million before deducting underwriting discounts and commissions and offering expenses. All of the common shares and pre-funded warrants are being offered by Axovant. In connection with this offering, Axovant has granted the underwriters a 30-day option to purchase up to an additional 2,600,000 of its common shares on the same terms and conditions. The offering is expected to close on February 24, 2020, subject to customary closing conditions.

Axovant Gene Therapies Announces Pricing of $65 Million Public Offering

NEW YORK and BASEL, Switzerland, Feb.  19, 2020  (GLOBE NEWSWIRE) -- Axovant Gene Therapies Ltd. (Nasdaq: AXGT) ("Axovant") today announced that it has commenced an underwritten public offering of its common shares and pre-funded warrants to purchase its common shares. In connection with this offering, Axovant expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the aggregate number of common shares plus the common shares underlying the pre-funded warrants in the offering on the same terms and conditions. All of the common shares and pre-funded warrants are being offered by Axovant.

Axovant Gene Therapies Announces Commencement of Public Offering

NEW YORK and BASEL, Switzerland, Feb.  10, 2020  (GLOBE NEWSWIRE) -- Axovant Gene Therapies Ltd. (NASDAQ: AXGT), a clinical-stage company developing innovative gene therapies, today provided financial results for its third fiscal quarter ended December 31, 2019.

Axovant Announces Financial Results for Third Fiscal Quarter and Nine Months Ended December 31, 2019

NEW YORK and BASEL, Switzerland, Jan.  13, 2020  (GLOBE NEWSWIRE) -- Axovant Gene Therapies Ltd. (NASDAQ: AXGT), a clinical-stage company developing innovative gene therapies for neurological diseases, today announced recent progress in its gene therapy programs, including a 12-month update on its Parkinson’s program.

Axovant Announces Positive 12-month Data on AXO-Lenti-PD and  Provides Updates Across Gene Therapy Pipeline Programs

What Makes Axovant (AXGT) a New Buy Stock

NEW YORK and BASEL, Switzerland, Dec.  19, 2019  (GLOBE NEWSWIRE) -- Axovant Gene Therapies Ltd. (NASDAQ: AXGT) today announced preliminary findings from an expanded access treatment in which a single patient with GM1 gangliosidosis was administered investigational AXO-AAV-GM1 gene therapy.

Axovant Provides Clinical Program Update for AXO-AAV-GM1, a Novel Investigational Gene Therapy for GM1 Gangliosidosis

The FDA grants Orphan Drug status to Axovant's (AXGT) gene therapy candidate, AXO-AAV-GM1, being developed for the treatment of GM1 gangliosidosis. Shares decline despite the positive news.

Axovant's GM1 Gangliosidosis Candidate Gets Orphan Drug Tag

NEW YORK and BASEL, Switzerland, Nov.  18, 2019  (GLOBE NEWSWIRE) -- Axovant Gene Therapies Ltd. (NASDAQ: AXGT), a clinical-stage company developing innovative gene therapies, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for the Company’s investigational gene therapy, AXO-AAV-GM1, for the treatment of GM1 gangliosidosis. GM1 gangliosidosis is a progressive and fatal pediatric lysosomal storage disorder caused by mutations in the GLB1 gene leading to impaired production of the beta-galactosidase enzyme. The Company is planning to complete enrollment of patients in Part A of the AXO-AAV-GM1 registrational program evaluating safety and efficacy and expects to announce 6-month data from Part A in mid-2020. 

Axovant Gene Therapies Receives Orphan Drug Designation from FDA for AXO-AAV-GM1 for the Treatment of GM1 Gangliosidosis

Axovant Gene Therapies has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.

Axovant Gene Therapies Enters Oversold Territory

NEW YORK and BASEL, Switzerland, Oct.  10, 2019  (GLOBE NEWSWIRE) -- Axovant Gene Therapies, Ltd. (NASDAQ: AXGT), a clinical-stage company developing innovative gene therapies, today announced upcoming presentations regarding its investigational gene therapy programs, AXO-Lenti-PD, AXO-AAV-GM1 and AXO-AAV-GM2, at the European Society of Gene and Cell Therapy (ESGCT) 27th Annual Congress, held in Barcelona, Spain, October 22-25, 2019.

Axovant Gene Therapies Announces Upcoming Presentations at the European Society of Gene and Cell Therapy 27th Annual Congress

Axovant (AXGT) Upgraded to Buy: Here's What You Should Know

In the latest trading session, Axovant (AXGT) closed at $6.61, marking a +0.46% move from the previous day.

Axovant (AXGT) Gains As Market Dips: What You Should Know

BASEL, Switzerland, Sept.  25, 2019  (GLOBE NEWSWIRE) -- Axovant Gene Therapies Ltd. (Nasdaq: AXGT), a clinical-stage company developing innovative gene therapies, today announced that Parag Meswani, Pharm.D., senior vice president, commercial strategy & operations, will present at the annual Cell & Gene Meeting on the Mesa at 4:30 PM PT on October 3, 2019 in Carlsbad, California.

Axovant Gene Therapies to Present at 2019 Cell & Gene Meeting on the Mesa

Axovant (AXGT) closed at $7.53 in the latest trading session, marking a -1.31% move from the prior day.

Axovant (AXGT) Stock Moves -1.31%: What You Should Know

Gene therapy is an emerging therapeutic area, and Axovant Gene Therapies Ltd (NASDAQ: AXGT) is an attractive play on the sector, according to Baird.

Axovant Analyst Turns Bullish Ahead Of Q4 Gene Therapy Data Readouts

On Axovant's (AXGT) first-quarter fiscal 2019 earnings call, investor focus will be on its progress with the investigational pipeline candidates designed to treat debilitating neurological diseases.

Axovant (AXGT) to Post Q1 Earnings: What's in the Cards?

Axovant (AXGT) closed the most recent trading day at $7.38, moving +0.68% from the previous trading session.

Axovant (AXGT) Outpaces Stock Market Gains: What You Should Know

As of late, it has definitely been a great time to be an investor Axovant Sciences.

News for Axovant Gene Therapies Ltd Stock (AXGT)